CVS Health Slashes FY24 Outlook; Stock Down 11% - Update
(RTTNews) - While reporting financial results for the first quarter on Wednesday, CVS Health (CVS) slashed its earnings and adjusted earnings guidance for the full-year 2024, reflecting the potential for continued elevated medical cost trends in the remainder of 2024.
For fiscal 2024, the company now projects earnings of atleast $5.64 per share and adjusted earnings of atleast $7.00 per share.
Previously, the company expected earnings of atleast $7.06 per share and adjusted earnings of atleast $8.30 per share.
On average, 27 analysts polled by Thomson Reuters expect the company to report earnings of $8.28 per share for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
CVS Health Reportedly Mulls Breakup, To Cut 2,900 Jobs
CVS Health Corp. is conducting a strategic review of options including a possible breakup amid issues from its drugstore chain and Aetna health insurance arm, reports said citing person familiar with the matter. The company also plans to reduce its workforce by less than 1 percent, which would affect around 2,900 employees, as part of its cost-cutting efforts.
RTTNews
|
Pred 85 dňami
CVS Offers Updated 2024-2025 COVID-19 And Flu Vaccines
CVS Health Corp. announced Wednesday the availability of updated 2024-2025 COVID-19 vaccines and flu vaccines at CVS Pharmacy and MinuteClinic locations across the United States. The U.S. Food and Drug Administration recently approved and granted emergency use authorization or EUA for updated Covid vaccines (2024-2025 formula) from Pfizer Inc. and ModernaTX Inc. for use against currently...
RTTNews
|
Pred 119 dňami
P&G Recalls 8.2 Mln Defective Laundry Detergent Packets
Consumer goods giant Procter & Gamble Co. has called back around 8.2 million defective bags of Tide, Gain, Ace and Ariel laundry detergent packets distributed in the United States citing risk of serious injury, the U.S. Consumer Product Safety Commission announced. In addition, about 56,741 were sold in Canada. According to the agency, the outer packaging meant to prevent access to the contents...
RTTNews
|
Pred 261 dňami
Walgreens, CVS To Sell Abortion Pill Mifepristone Starting In March
Pharmacy majors Walgreens Boot Alliance Inc. and CVS Health Corp. will start selling abortion pill mifepristone this month at stores in several states where it is legal. Both companies have received certification from the U.S. Food and Drug Administration to dispense the pill at their retail pharmacies.
RTTNews
|
Pred 296 dňami
CVS Health Lowers FY24 Outlook - Update
While reporting financial results for the fourth quarter on Wednesday, CVS Health (CVS) lowered its earnings and adjusted earnings guidance for the full-year 2024.
RTTNews
|
Pred 322 dňami
CVS Health Confirms Tom Cowhey As New CFO
CVS Health (CVS) announced Friday that Senior Vice President of Corporate Finance and interim CFO, Tom Cowhey, has been formally appointed the company's next CFO.
RTTNews
|
Pred 355 dňami
CVS To Remove Some Cold, Cough Medicines With Phenylephrine
CVS Health is removing certain over-the-counter or OTC cold and cough products with phenylephrine as the only active ingredient from its Pharmacy stores, reports said. The decision follows the U.S. Food and Drug Administration Advisory Committee's position on oral phenylephrine or PE.
RTTNews
|
Pred 432 dňami
FDA Warns CVS Health, Walgreens Against Unapproved Eye Products
The U.S. Food and Drug Administration has warned eight companies including CVS Health and Walgreens Boots Alliance, Inc. against manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. The agency has issued warning letters to these companies as part of its ongoing effort to protect Americans from potentially harmful ophthalmic products.
RTTNews
|
Pred 469 dňami
